Skip to main content

Table 1 Baseline Characteristics

From: Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas

Characteristic

All patients (n = 25)

Age, year (range)

49 (30–72)

Gender: male, no. (%)

11 (44)

Race

 

 Caucasian, no. (%)

22 (88)

 Asian, no. (%)

1 (4)

 Black, no. (%)

0 (0)

 Latino/Hispanic, no. (%)

1 (4)

 Other, no. (%)

1 (4)

Diagnosis

 

 Glioblastoma, no. (%)

13 (52)

 Anaplastic astrocytoma, no. (%)

7 (28)

 Anaplastic oligodendroglioma, no. (%)

2 (8)

 Unspecified high grade glioma, no. (%)

2 (8)

 Gliosarcoma, no. (%)

1 (4)

Performance status, KPS (range)

80 (50–100)

Number of prior therapies, median (range)

4 (1–9)

Previously received bevacizumab, no. (%)

19 (76)

MGMT status

 

 Methylated, no. (%)

4 (16)

 Unmethylated, no. (%)

12 (48)

 Unknown, no. (%)

9 (36)

IDH1 Status

 

 IDH1 Mutated, no. (%)

10 (40)

 IDH1 Wild Type, no. (%)

9 (36)

 Unknown, no. (%)

6 (24)

Number of mutations by MSK-Impact, median (range)

7 (3–58)

PD-1 inhibitor

 

 Pembrolizumab, no. (%)

25 (100)

Number of doses administered, median (range)

3 (1–14)

Concomitant therapy

 

 Pembrolizumab monotherapy, no. (%)

6 (24)

 Bevacizumab, no. (%)

17 (68)

 Cytotoxic chemotherapy + bevacizumab, no. (%)

2 (8)

 Receiving dexamethasone at time of first dose, no. (%)

14 (56%)